Exton, PA – According to filings with the U.S. Securities and Exchange Commission, Immunome is raising $11,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Purnanand Sarma played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Immunome

Immunome is a biotechnology company with a growing pipeline of cancer immunotherapies fueled by the human immune system. Our unique and powerful immunotherapy discovery engine leverages most highly educated immune systems from patients who have already learned how to fight off their disease. This proprietary technology platform enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens. We then employ a battery of high-content screening technologies to identify specific and high-affinity antibodies that offer significant therapeutic potential to change the way we treat cancer.

To learn more about Immunome, visit http://immunome.com/

Contact:
Purnanand Sarma, Chief Executive Officer
610-321-3700
psarma@immunome.com
https://www.linkedin.com/in/purnanand-sarma-6412444/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved